Now enrolling — The GALACTIC Registry, a multi-center dd-cfDNA study.Learn more →

Enabling sharper dd-cfDNA insight closer to your transplant program.

GraftAssure™ uses droplet digital™ PCR-based technology to support donor-derived cell-free DNA testing pathways for transplant clinicians and HLA laboratories.

Built for the teams closest to transplant care.

Whether you’re a transplant clinician or surgeon exploring clinical evidence and use cases, or an HLA laboratory professional evaluating workflow, validation, and implementation, GraftAssure is designed to provide the most freedom for your lab.

Transplant Clinicians

Understand graft injury signals earlier in the care pathway.

Explore the evidence behind dd-cfDNA, relative and absolute quantification, and use cases such as surveillance, for-cause assessment, and longitudinal monitoring.

HLA Laboratories

Evaluate workflow, access, and implementation fit.

Compare an in-house RUO kit pathway with a send-out access model and review instrumentation, workflow, and resource requirements.

Choose the GraftAssure path that fits your program.

In-House

Designed for advanced HLA labs bringing dd-cfDNA testing in‑house.

The GraftAssureIQ dd-cfDNA Test Kit (RUO) is designed for laboratories that want control over sample handling, testing schedule, data generation, and research workflows.

Generate results in as little as 8–12 hours, depending on sample volume.
Report relative (%) and absolute (copies/mL) dd-cfDNA values from a single sample.
Support publication, biomarker exploration, and future menu expansion.

Send-Out

For labs that want access but don’t have the resources for in-house development.

GraftAssureCore is a laboratory-developed test positioned for institutions that value dd-cfDNA innovation but may not have the resources, staffing, or infrastructure to develop and validate their own assay.

Demonstrated concordant results to established NGS assays
Shown to have the highest positive predictive value may allow you to rule-in a clinical decision
Lowest limit of quantification enables detection of dd-cfDNA changes below thresholds

Ready to bring dd-cfDNA insight to your program?

Talk with iMDx about workflow, access, and whether GraftAssureIQ or GraftAssureCore is the right starting point.